About Us







BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Posted: February 5, 2021 at 11:49 pm


PALO ALTO, Calif., Feb. 05, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, today announced that on February 1, 2021, the compensation committee of BridgeBio’s board of directors granted 11 new employees restricted stock units for an aggregate of 16,772 shares of the Company’s common stock. All of the above-described awards were made under BridgeBio’s 2019 Inducement Equity Plan (the Plan).

Read more:
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Related Post

No Comments

No comments yet.

Sorry, the comment form is closed at this time.